title: Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling".
abstract: Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) play important roles in tumor growth, which has stimulated efforts toward the design of targeted cancer therapeutics that inhibit their function. A growing body of literature indicates that EGFR and mTOR are also essential to support a functional innate immune response. Hence, although combination therapies that block both EGFR and mTOR may have improved activity against tumors, they may also place patients at risk of fulminant infections. We discuss data supporting this hypothesis.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
authors.forename: Barbara
authors.initials: B
authors.lastname: Burtness
authors.forename: Shanthi
authors.initials: S
authors.lastname: Marur
authors.forename: Julie E
authors.initials: JE
authors.lastname: Bauman
authors.forename: Erica A
authors.initials: EA
authors.lastname: Golemis
authors.forename: Ranee
authors.initials: R
authors.lastname: Mehra
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Cohen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000068338:Everolimus; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy*; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D051196:Toll-Like Receptor 3 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D051196:Toll-Like Receptor 3; D000068338:Everolimus; D066246:ErbB Receptors; D000068818:Cetuximab; D020123:Sirolimus